Search clinical trials for: Inadequate Response to Antidepressant Therapy

Total 474671 results

Clexio Biosciences Ltd.

Recruiting

A Study of CLE-100 (Oral Esketamine) as an Adjunctive Treatment to Standard Antidepressants for Major Depressive Disorder (SOLEO)

Adjunctive Treatment of Major Depressive Disorder (MDD)

United States
Janssen Research & Development, LLC

Recruiting

A Study in Participants With Major Depressive Disorder (MDD) With Anhedonia and Inadequate Response to Current Antidepressant Therapy Including a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin Norepinephrine Reuptake Inhibitor (SNRI) (VENTURA-RWE)

Depressive Disorder, Major

United States, Korea, Republic of, Spain, Argentina, Sweden, Germany, Canada, France, Brazil
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-2)

Anhedonia | Depressive Disorder, Major

Korea, Republic of, United States, China, Taiwan, Canada, Slovakia, Poland, Argentina, Bulgaria, Czechia, South Africa, United Kingdom, France, Brazil
Janssen Research & Development, LLC

Recruiting

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy (VENTURA-1)

Anhedonia | Depressive Disorder, Major

United States, Spain, Bulgaria, Italy, Poland, Belgium, Argentina, Czechia, Hungary, Sweden, Brazil, Australia, Portugal
Janssen Research & Development, LLC

Active, not recruiting

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adolescents With Major Depressive Disorder Who Have an Inadequate Response to Selective Serotonin Reuptake Inhibitor (SSRI) and Psychotherapy

Depressive Disorder, Major

United States, Spain, Italy, United Kingdom
AbbVie

Completed

Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Major Depressive Disorder

United States, Bulgaria, Estonia, Germany, Hungary, Ukraine, United Kingdom
AbbVie

Completed

The Objective of This Study is to Evaluate the Efficacy, Safety and Tolerability of Cariprazine as an Adjunctive Treatment to Antidepressant Therapy (ADT) in Patients With Major Depressive Disorder (MDD) Who Have Had an Inadequate Response to Antidepressants Alone

Major Depressive Disorder

United States, Canada, Czechia, Finland, Poland, Puerto Rico, Serbia, Slovakia
AbbVie

Withdrawn

A Study To Assess Adverse Events and Change in Disease Activity With Oral Cariprazine When Added to Antidepressant Therapies (ADTs) Compared to Placebo in Adult Participants With Generalized Anxiety Disorder (GAD) Who Have Had an Inadequate Response to ADTs Alone (CAR aGAD Ph 2)

Generalized Anxiety Disorder

United States
Avanir Pharmaceuticals

Completed

Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment

Depressive Disorder, Treatment-Resistant

United States
AstraZeneca

Completed

A Study to Assess the Effect and Safety of AZD6765 in Patients With Major Depressive Disorder

Major Depressive Disorder

United States, South Africa, Chile, Slovakia
Hoffmann-La Roche

Completed

MARIGOLD Study: A Study of RO4917523 Versus Placebo as Adjunctive Therapy in Patients With Major Depressive Disorder and an Inadequate Response to Ongoing Antidepressant Therapy

Major Depressive Disorder

Germany, United States, Taiwan, Mexico, Poland, Russian Federation, Chile, Japan, Romania
H. Lundbeck A/S

Completed

Study of Brexpiprazole as Adjunctive Treatment of Irritability in Patients With Major Depressive Disorder and an Inadequate Response to Antidepressant Therapy

Irritability | Major Depressive Disorder

United States
AstraZeneca

Terminated

A Study to Assess the Safety and Effect of TC-5214 in Patients With Major Depressive Disorder.

Major Depressive Disorder

United States, Estonia, Japan, Finland, India
AstraZeneca

Completed

Description of Treatment Management of Patients With Major Depressive Disorder and Inadequate Response (MADDRE)

Major Depressive Disorder

Greece
Sanofi

Recruiting

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor (AQUA)

Dermatitis Atopic

United States, Chile, Canada, United Kingdom
Merck Sharp & Dohme LLC

Recruiting

A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)

Essential Thrombocythemia

Israel, Australia, Hong Kong, Japan, New Zealand, Taiwan, Korea, Republic of, United States, Spain
Medical University of Vienna

Recruiting

Prediction of Antidepressant Effects of Electroconvulsive Therapy

Depressive Disorder, Major

Austria
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Efficacy, Safety, and Drug Levels of Oral Ozanimod in Pediatric Participants With Moderately to Severely Active Crohn's Disease With an Inadequate Response to Conventional Therapy

Crohn Disease

United States, Belgium, Hungary, France, Canada, Spain, Australia, Germany, Poland, United Kingdom
Assistance Publique - Hôpitaux de Paris
URC-CIC Paris Descartes Necker Cochin

Not yet recruiting

Study of Salvage Therapy to Treat Patients With Granulomatosis With Polyangiitis (SATELITE)

Granulomatosis With Polyangiitis | Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis

France
Janssen Research & Development, LLC

Terminated

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Korea, Republic of, Malaysia, Poland, Finland, Chile, Argentina, Slovakia, Ukraine, Denmark
Janssen Research & Development, LLC

Active, not recruiting

A Study of Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant and Long-term Safety Extension Treatment With Seltorexant

Depressive Disorder, Major

United States, Taiwan, Czechia, Spain, Mexico, South Africa, Colombia, Russian Federation, Brazil, Bulgaria, Sweden
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Clinical Effects of Multiple Rising Subcutaneous Doses of BI 655064 in Healthy Volunteers and in Rheumatoid Arthritis Patients With Prior Inadequate Response to Methotrexate Therapy

Healthy | Arthritis, Rheumatoid

Germany, Netherlands, New Zealand, Poland, Spain, Czechia
BioCryst Pharmaceuticals

Terminated

BCX9930 for Treatment of PNH in Subjects With Inadequate Response to C5 Inhibitor Therapy (REDEEM-1)

Paroxysmal Nocturnal Hemoglobinuria (PNH)

United Kingdom, Hungary, France, Italy, Spain
Janssen Research & Development, LLC

Completed

A Study of Seltorexant Compared to Quetiapine XR as Adjunctive Therapy to Antidepressants in Adult and Elderly Participants With Major Depressive Disorder With Insomnia Symptoms Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Belgium, Czechia, Ukraine, Poland, Malaysia, Serbia, Bulgaria, Argentina, Lithuania, Slovakia, Russian Federation, Canada, United Kingdom, Latvia
Hoffmann-La Roche

Completed

An Efficacy and Safety Study of Subcutaneous Tocilizumab in Combination With Methotrexate (MTX) and as Monotherapy Versus MTX in Participants With Moderate to Severe Rheumatoid Arthritis With Inadequate Response to Current Disease-Modifying Antirheumatic Drug (DMARD) Therapy

Rheumatoid Arthritis

China
AbbVie

Active, not recruiting

A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) (SELECT - PsA 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belarus, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, China, Colombia, Croatia, Czechia, Estonia, Germany, Greece, Hong Kong, Hungary, Ireland, Israel, Italy, Japan, Korea, Republic... and more
Janssen Research & Development, LLC

Terminated

A Standard of Care Study of Patients With Major Depressive Disorder Who Have Had an Inadequate Response to a Selective Serotonin Reuptake/Serotonin-Norepinephrine Reuptake Inhibitor Antidepressant

Depressive Disorder, Major

United States, United Kingdom
CymaBay Therapeutics, Inc.

Completed

RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, France, Korea, Republic of, Denmark, Australia, Italy, United Kingdom, Belgium, Canada, Russian Federation, Romania, Germany, Hungary, Mexico, Turkey, Argentina, Austria, Chile, Czechia, Greece, Israel, New Zealand and more
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Efficacy and Safety of JNJ-42847922 as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States, Bulgaria, Ukraine, Russian Federation, Germany, Finland, Japan, France
Rush University Medical Center

Completed

Adjunctive Mixed Salts Amphetamine for Depressed Adults With Incomplete Response to Current Antidepressant Therapy

Major Depressive Disorder

United States
Jazz Pharmaceuticals

Terminated

Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment

Schizophrenia

United States, Spain, Poland, Serbia
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (KEEPsAKE2)

Psoriatic Arthritis (PsA)

United States, Argentina, Australia, Belgium, Brazil, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Israel, Italy, Netherlands, New Zealand, Poland, Portugal, Puerto Rico, Singapore, South Africa, Spain, Sweden, United...
AbbVie

Active, not recruiting

A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1)

Psoriatic Arthritis

United States, Argentina, Australia, Belgium, Bosnia and Herzegovina, Brazil, Bulgaria, Canada, Chile, Croatia, Czechia, Denmark, Estonia, Finland, Germany, Greece, Israel, Italy, Korea, Republic of, Latvia, Lithuania, Malaysia, Mexico and more
Janssen Research & Development, LLC

Completed

A Study to Compare the Efficacy, Safety, and Tolerability of JNJ-42847922 Versus Quetiapine Extended-Release as Adjunctive Therapy to Antidepressants in Adult Participants With Major Depressive Disorder Who Have Responded Inadequately to Antidepressant Therapy

Depressive Disorder, Major

United States
Ad scientiam

Terminated

Major Depressive Disorder: Early Prediction of Non-response to Antidepressant Therapy Via a Mobile Digital Scale (REDRESS)

Depressive Disorder, Major

France
CymaBay Therapeutics, Inc.

Completed

ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA)

Primary Biliary Cholangitis

United States, Spain, United Kingdom, Israel, France, Korea, Republic of, Australia, Italy, Hungary, Germany, Romania, Belgium, Canada, Greece, New Zealand, Austria, Serbia, Russian Federation, Argentina, Mexico, Netherlands, Chile, Polan...
Galapagos NV

Completed

A Study Evaluating the Effects of GLPG3970 Given as an Oral Treatment for 6 Weeks in Adults With Moderately to Severely Active Rheumatoid Arthritis and an Inadequate Response to Methotrexate (LADYBUG)

Rheumatoid Arthritis

Ukraine, Georgia, Bulgaria, Poland
ACADIA Pharmaceuticals Inc.

Terminated

Extension Study of Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Slovakia, South Africa, Ukraine, United Kingdom
Gilead Sciences
Galapagos NV

Terminated

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Psoriatic Arthritis Who Have an Inadequate Response or Are Intolerant to Biologic DMARD Therapy (PENGUIN 2)

Psoriatic Arthritis

Korea, Republic of, United States, Australia, Belgium, Canada, Czechia, Hungary, Japan, Poland, Spain, Taiwan
Eisai Co., Ltd.
FUJIFILM Toyama Chemical Co., Ltd.

Completed

A Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Combination Therapy of T-614 and Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

Rheumatoid Arthritis

Japan
Janssen Pharmaceutica N.V., Belgium

Completed

A Study of Guselkumab in Participants With Active Psoriatic Arthritis and an Inadequate Response to Anti-Tumor Necrosis Factor Alpha (Anti-TNF Alpha) Therapy (COSMOS)

Arthritis, Psoriatic

Belgium, France, Israel, Italy, Germany, Bulgaria, Spain, Poland, Russian Federation, United Kingdom, Ukraine, Hungary, Portugal, Greece
ACADIA Pharmaceuticals Inc.

Completed

Adjunctive Pimavanserin in Subjects With Major Depressive Disorder and Inadequate Response to Antidepressant Treatment

Adjunctive Treatment of Major Depressive Disorder

United States, Serbia, Finland, Poland, Russian Federation, Ukraine, United Kingdom, Slovakia, South Africa
The University of Hong Kong

Completed

Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy

Type 2 Diabetes | Ketonemia

Hong Kong
Gilead Sciences
Galapagos NV

Withdrawn

Study to Evaluate the Efficacy and Safety of Filgotinib in Participants With Active Ankylosing Spondylitis Who Have an Inadequate Response to Biologic Disease-Modifying Antirheumatic Drug Therapy (SEALION1-IR)

Ankylosing Spondylitis
Genentech, Inc.
Roche Pharma AG

Terminated

A Study to Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy (FEATURE)

Rheumatoid Arthritis
Archigen Biotech Limited

Completed

PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis

United States, Korea, Republic of, Hungary, Poland, Czechia, Spain, Bosnia and Herzegovina, Bulgaria, Germany, India, Mexico
Pfizer

Completed

Study of CP-690,550 Versus Placebo In Rheumatoid Arthritis Patients On Background Methotrexate With Inadequate Response To Tumor Necrosis Factor (TNF) Inhibitors

Arthritis, Rheumatoid

Australia, United States, Austria, Germany, Ireland, Brazil, Spain, Taiwan, Belgium, Canada, France, Italy, Korea, Republic of, Puerto Rico
Hoffmann-La Roche

Completed

A Study of Tocilizumab (RoActemra/Actemra) in Monotherapy or in Combination With Methotrexate or Other Non-Biologic DMARDs in Participants With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biologic DMARD Therapy or the First Anti-TNF Biologic Agent (ACT-MOVE)

Rheumatoid Arthritis

United Kingdom
Eli Lilly and Company

Completed

A Study for Patients With Rheumatoid Arthritis on Methotrexate (MTX) With an Inadequate Response to TNFα Inhibitor Therapy

Arthritis, Rheumatoid

United States, Argentina, Germany, Puerto Rico, Mexico, Belgium, Poland, Brazil, Austria, Canada
AbbVie

Withdrawn

Changes in Ultrasonographic Assessment of Inflammation Upon Initiation of Adalimumab Combination Therapy in Chinese Rheumatoid Arthritis (RA) Patients With Inadequate Response to Methotrexate

Rheumatoid Arthritis (RA)

China

3

Subscribe